Ailing InVivo CEO steps down; Ivantis raises $5M for eye stent trials;

@FierceMedDev: Bard settles vaginal mesh suit as thousands pend. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Israel's InSightec is expanding into Canada with its surgery-free uterine fibroid treatment. News | Follow @DamianFierce

@MarkHFierce: We're launching a new diagnostics report in less than a week, and I'll be writing it. Sign up here | Follow @MarkHFierce

@MichaelGFierce: FDA clears Novo Nordisk's insulin injection pen for children. Item | Follow @MichaelGFierce

> InVivo Therapeutics ($NVIV) CEO Francis Reynolds is stepping down due to his medical condition, and Vivus ($VVUS) Chairman Michael Astrue is filling in while the company looks for a full-time chief. News

> Ivantis, developer of an eye stent to treat glaucoma, raised a $5 million Series B to help propel further clinical trial work. Item

> Dilon Diagnostics will distribute a number of Digirad's ($DRAD) nuclear imaging cameras. Item

> Molecular diagnostics company Atossa Genetics ($ATOS) will ring the Nasdaq closing bell to celebrate its Nov. 8, 2012 initial listing. Item

> eNeuras Therapeutics raised a small amount of new funding as it continues to develop a portable transcranial magnetic stimulation device to treat migraines. Item

> The entire amount of total knee replacements performed in the U.S. in 2009 saved $12 billion for patients and employers. Story

Biotech News

@FierceBiotech: Shire and Santaris extend their strategic alliance to discover, develop LNA-drugs in the rare disease field. Press release | Follow @FierceBiotech

@JohnCFierce: The latest on the Onyx buyout: Yes they are. No they aren't. Say what? Item | Follow @JohnCFierce

@EmilyMFierce: This week's career moves in biopharma. Chutes & Ladders | Follow @EmilyMFierce

> GlaxoSmithKline ponders future of Crohn's disease drug after PhIII flop. Report

> 3-D printing creates living tissue cells, holds promise for medical research. Story

> Vical restructures, chops 47 jobs after PhIII immunotherapy flop. Article

> Mystery doc cited for handing insider trial info to SAC trader. Report

Pharma News

@FiercePharma: Merck has the Zilmax PR right: Animal advocate Temple Grandin to consult on livestock drug's safety. More | Follow @FiercePharma

@EricPFierce: Regeneron takes a "byte" out of excess manufacturing capacity in Ireland. ICYMI yesterday | Follow @EricPFierce

@CarlyHFierce: Amid Purdue criticism, CVS cuts opioid access for 'risky' prescribers. ICYMI yesterday | Follow @CarlyHFierce

> Takeda presses on in emerging markets with Peru operation. Story

> SAC fund manager alleged to have not 1 but 2 docs feeding him insider info. More